Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Apr 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Apr 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics , Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com .
Amtagvi® and its accompanying design marks, Proleukin ® , Iovance ® , and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com .
Overview
This position is integral to the continued and planned future growth of Iovance Biotherapeutics’ Cell Therapy Manufacturing Center and capabilities. The Senior Manager, Cost Accounting is responsible for overseeing cost accounting (including cost of goods sold, bill of materials and inventory costing. The Senior Manager provides reporting and analysis to the corporate finance and accounting team, including the SVP, Finance and CFO, to support the strategic and operational planning. The Senior manager works with Manufacturing Finance, Corporate Accounting and Corporate FP&A teams to support the monthly close processes and quarterly external financial reporting as well as to assure strong linkage of data reported and budgeted results.
Essential Functions and Responsibilities
• Oversee monthly/quarterly close process for general ledger accounts.
• Prepare & analyze financial statements for the Company
• Ownership of overhead cost pool accumulation and allocation/absorption, as well as analysis of related costs and results.
• Ensure and coordinate timely monthly and quarterly cost accounting close activities for inventory and cost of sales, including reconciliations and review of reconciliations where appropriate, including generating journal entries where appropriate.
• Oversee quarterly and year-end physical inventory process with the operations team.
• Coordinate calculation and recording of appropriate inventory reserves working with operations team.
• Collaborate with Internal Audit with the ownership and execution of Sarbanes-Oxley compliance for inventory and cost of sales, as well as ongoing reviews for potential enhancements and improvements.
• Support the forecast and budget process with timely inputs related to product volumes, purchases, expected overhead pool, costs per unit and cost of sales.
• Analysis of manufacturing organization spending, as well as support of the forecast process, and support of the FP&A organization in the preparation of materials for the monthly and quarterly financial review meetings.
• Prepare monthly and quarterly PBC schedules to support the audit and interim reviews, including working with audit firm on deliverables and related questions
• Proactively identify and analyze opportunities to improve results and facility processes.
• Support any internal and external financia
Apply with SponsorApply